Advances and opportunities in nanoimaging agents for the diagnosis of inflammatory lung diseases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Jiang XQ, Mei XD, Feng D. Air pollution and chronic airway diseases: what should people know and do? J. Thorac. Dis. 8(1), E31–40 (2016).
  MedlineGoogle Scholar
• 2. Cingi C, Muluk NB, Editors. Acute viral rhinitis. In: All Around Nose. Springer Nature Switzerland, Cham, Switzerland doi:10.1007/978-3-030-21217-9_23(199–202) (2019).
  Google Scholar
• 3. Strashun S, D'sa S, Foley D, Hannon J, Murphy AM, O'Gorman CS. Physical illnesses associated with childhood homelessness: a literature review. Ir. J. Med. Sci. 189(4), 1331–1336 (2020).
  MedlineGoogle Scholar
• 4. Rather LJ. Acute inflammation. JAMA 225(9), 1128–1129 (1973).
  Google Scholar
• 5. Guo S, Dipietro LA. Factors affecting wound healing. J. Dent. Res. 89(3), 219–229 (2010).
  Medline CASGoogle Scholar
• 6. Kalchiem-Dekel O, Galvin JR, Burke AP, Atamas SP, Todd NW. Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. J. Clin. Med. 7(12), 476 (2018).
  MedlineGoogle Scholar
• 7. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 15(1), 79–94 (2002).
  MedlineGoogle Scholar
• 8. Bartholmai BJ, Raghunath S, Karwoski RA et al. Quantitative computed tomography imaging of interstitial lung diseases. J. Thorac. Imaging 28(5), 298–307 (2013).
  MedlineGoogle Scholar
• 9. Mclean-Tooke A, Moore I, Lake F. Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges. Clin. Transl. Immunol. 8(11), e1086 (2019).
  MedlineGoogle Scholar
• 10. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370(9589), 765–773 (2007).
  MedlineGoogle Scholar
• 11. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364(9435), 709–721 (2004).
  MedlineGoogle Scholar
• 12. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 4, 435–459 (2009).
  Medline CASGoogle Scholar
• 13. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157(4 Pt 1), 1301–1315 (1998).
  Medline CASGoogle Scholar
• 14. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497–506 (2020).
  Medline CASGoogle Scholar
• 15. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin. Immunol. 215, 108427 (2020).
  Medline CASGoogle Scholar
• 16. Peat JK, Haby M, Spijker J, Berry G, Woolcock AJ. Prevalence of asthma in adults in Busselton, Western Australia. BMJ 305(6865), 1326–1329 (1992).
  Medline CASGoogle Scholar
• 17. Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat. Rev. Immunol. 15(1), 57–65 (2015).
  Medline CASGoogle Scholar
• 18. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103(6), 779–788 (1999).
  Medline CASGoogle Scholar
• 19. He Y, Shi J, Yi W et al. Discovery of a highly potent glucocorticoid for asthma treatment. Cell Discov. 1, 15035 (2015).
  Medline CASGoogle Scholar
• 20. Zheng M. Classification and pathology of lung cancer. Surg. Oncol. Clin. N. Am. 25(3), 447–468 (2016).
  MedlineGoogle Scholar
• 21. De Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health 8(2), e180–e190 (2020).
  MedlineGoogle Scholar
• 22. Gomes M, Teixeira AL, Coelho A, Araujo A, Medeiros R. The role of inflammation in lung cancer. Adv. Exp. Med. Biol. 816, 1–23 (2014).
  Medline CASGoogle Scholar
• 23. Weatherley ND, Eaden JA, Stewart NJ et al. Experimental and quantitative imaging techniques in interstitial lung disease. Thorax 74(6), 611–619 (2019).
  MedlineGoogle Scholar
• 24. Veldhoen S, Weng AM, Knapp J et al. Self-gated non-contrast-enhanced functional lung MR Imaging for quantitative ventilation assessment in patients with cystic fibrosis. Radiology 283(1), 242–251 (2017).
  MedlineGoogle Scholar
• 25. Baues M, Dasgupta A, Ehling J et al. Fibrosis imaging: current concepts and future directions. Adv. Drug Deliv. Rev. 121, 9–26 (2017).
  Medline CASGoogle Scholar
• 26. Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188(6), 733–748 (2013).
  MedlineGoogle Scholar
• 27. Scherer PM, Chen DL. Imaging pulmonary inflammation. J. Nucl. Med. 57(11), 1764–1770 (2016).
  Medline CASGoogle Scholar
• 28. Colombi D, Dinkel J, Weinheimer O et al. Visual vs fully automatic histogram-based assessment of idiopathic pulmonary fibrosis (IPF) progression using sequential multidetector computed tomography (MDCT). PLOS ONE 10(6), e0130653 (2015).
  MedlineGoogle Scholar
• 29. Gould G, Redpath A, Ryan M et al. Parenchymal emphysema measured by CT lung density correlates with lung function in patients with bullous disease. Eur. Respir. J. 6(5), 698–704 (1993).
  Medline CASGoogle Scholar
• 30. Maldonado F, Moua T, Rajagopalan S et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur. Respir. J. 43(1), 204–212 (2014).
  MedlineGoogle Scholar
• 31. Myall KJ, Mukherjee B, Castanheira AM et al. Persistent post–COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann. Am. Thorac. Soc. 18(5), 799–806 (2021).
  MedlineGoogle Scholar
• 32. Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir. Med. 8(3), 304–320 (2020).
  Medline CASGoogle Scholar
• 33. Koyama H, Ohno Y, Yamazaki Y et al. Quantitatively assessed CT imaging measures of pulmonary interstitial pneumonia: effects of reconstruction algorithms on histogram parameters. Eur. J. Radiol. 74(1), 142–146 (2010).
  MedlineGoogle Scholar
• 34. Baumann U, Routes JM, Soler-Palacín P, Jolles S. The lung in primary immunodeficiencies: new concepts in infection and inflammation. Front. Immunol. 9, 1837 (2018).
  MedlineGoogle Scholar
• 35. Romei C, Turturici L, Tavanti L et al. The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review. Eur. Resp. Rev. 27(150), 180062 (2018).
  Google Scholar
• 36. Jolles S, Carne E, Brouns M et al. FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin. Exp. Immunol. 187(1), 138–145 (2017).
  Medline CASGoogle Scholar
• 37. Withana NP, Ma X, Mcguire HM et al. Non-invasive imaging of idiopathic pulmonary fibrosis using cathepsin protease probes. Sci. Rep. 6(1), 1–10 (2016).
  MedlineGoogle Scholar
• 38. Reubi JC, Schär J-C, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27(3), 273–282 (2000).
  Medline CASGoogle Scholar
• 39. Chianelli M, Mather S, Martin-Comin J, Signore A. Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl. Med. Commun. 18(5), 437–455 (1997).
  Medline CASGoogle Scholar
• 40. Bondue B, Sherer F, Van Simaeys G et al. PET/CT with 18F-FDG–and 18F-FBEM–labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J. Nucl. Med. 56(1), 127–132 (2015).
  Medline CASGoogle Scholar
• 41. Désogère P, Tapias LF, Hariri LP et al. Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci. Transl. Med. 9(384), eaaf4696 (2017).
  MedlineGoogle Scholar
• 42. Marini TJ, Rubens DJ, Zhao YT et al. Lung ultrasound: the essentials. Radiol. Cardiothorac. Imaging 3(2), e200564 (2021).
  MedlineGoogle Scholar
• 43. Martin KH, Dayton PA. Current status and prospects for microbubbles in ultrasound theranostics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5(4), 329–345 (2013).
  Medline CASGoogle Scholar
• 44. Bokor D, Chambers JB, Rees PJ, Mant TG, Luzzani F, Spinazzi A. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest. Radiol. 36(2), 104–109 (2001).
  Medline CASGoogle Scholar
• 45. Ntziachristos V. Optical imaging of molecular signatures in pulmonary inflammation. Proc. Am. Thorac. Soc. 6(5), 416–418 (2009). • Quantitative optical imaging for in vivo lung inflammation.
  MedlineGoogle Scholar
• 46. Xu W, Wang D, Tang BZ. NIR-II AIEgens: a win-win integration towards bioapplications. Angew Chem. Int. Ed. Engl. 60(14), 7476–7487 (2021).
  Medline CASGoogle Scholar
• 47. Han X, Xu K, Taratula O, Farsad K. Applications of nanoparticles in biomedical imaging. Nanoscale 11(3), 799–819 (2019).
  Medline CASGoogle Scholar
• 48. Kumar NA, Anand BSS, Krishnamurthy G. Nanomaterials for medical imaging and in vivo sensing Springer series in biomaterials science and engineering. Nanomater. Biomed. Appl. 16 (2021).
  Google Scholar
• 49. Omlor AJ, Nguyen J, Bals R, Dinh QT. Nanotechnology in respiratory medicine. Respir. Res. 16, 64 (2015).
  MedlineGoogle Scholar
• 50. Da Silva AL, Cruz FF, Rocco PRM, Morales MM. New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys. Rev. 9(5), 793–803 (2017).
  MedlineGoogle Scholar
• 51. Liang Z, Ni R, Zhou J, Mao S. Recent advances in controlled pulmonary drug delivery. Drug Discov. Today 20(3), 380–389 (2015).
  Medline CASGoogle Scholar
• 52. Paranjpe M, Muller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: a review. Int. J. Mol. Sci. 15(4), 5852–5873 (2014).
  Medline CASGoogle Scholar
• 53. Fromen CA, Rahhal TB, Robbins GR et al. Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. Nanomedicine 12(3), 677–687 (2016).
  Medline CASGoogle Scholar
• 54. Costa A, Pinheiro M, Magalhaes J et al. The formulation of nanomedicines for treating tuberculosis. Adv. Drug Deliv. Rev. 102, 102–115 (2016).
  Medline CASGoogle Scholar
• 55. Shukla SD, Swaroop Vanka K, Chavelier A et al. Chronic respiratory diseases: an introduction and need for novel drug delivery approaches. In: Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems. Kamal Dua PMHWilliams KA (Eds). Elsevier Inc., Cambridge, MA, USA, 1–31 (2020).
  Google Scholar
• 56. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 600–612 (2003).
  Medline CASGoogle Scholar
• 57. Luo MX, Hua S, Shang QY. Application of nanotechnology in drug delivery systems for respiratory diseases (review). Mol. Med. Rep. 23(5), 325 (2021).
  Medline CASGoogle Scholar
• 58. Liu C, Jiang X, Gan Y, Yu M. Engineering nanoparticles to overcome the mucus barrier for drug delivery: design, evaluation and state-of-the-art. Med. Drug Discov. 12, 100110 (2021). • Discusses the fate of nanoparticles bypassing the lung barriers.
  CASGoogle Scholar
• 59. Ensign LM, Henning A, Schneider CS et al. Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol. Pharm. 10(6), 2176–2182 (2013).
  Medline CASGoogle Scholar
• 60. Li LD, Crouzier T, Sarkar A, Dunphy L, Han J, Ribbeck K. Spatial configuration and composition of charge modulates transport into a mucin hydrogel barrier. Biophys. J. 105(6), 1357–1365 (2013).
  Medline CASGoogle Scholar
• 61. Lim YH, Tiemann KM, Hunstad DA, Elsabahy M, Wooley KL. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8(6), 842–871 (2016).
  Medline CASGoogle Scholar
• 62. Aillon KL, El-Gendy N, Dennis C, Norenberg JP, McDonald J, Berkland C. Iodinated nanoclusters as an inhaled computed tomography contrast agent for lung visualization. Mol. Pharm. 7(4), 1274–1282 (2010).
  Medline CASGoogle Scholar
• 63. Badea CT, Athreya KK, Espinosa G et al. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLOS ONE 7(4), e34496 (2012).
  Medline CASGoogle Scholar
• 64. Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials 34(2), 470–480 (2013). •• Lung cancer computerized tomography imaging with a targeted nanoprobe with ligand.
  Medline CASGoogle Scholar
• 65. Haage P, Karaagac S, Adam G, Spuntrup E, Pfeffer J, Gunther RW. Gadolinium containing contrast agents for pulmonary ventilation magnetic resonance imaging: preliminary results. Invest. Radiol. 37(3), 120–125 (2002).
  MedlineGoogle Scholar
• 66. Pellico J, Lechuga-Vieco AV, Almarza E et al. In vivo imaging of lung inflammation with neutrophil-specific (68)Ga nano-radiotracer. Sci. Rep. 7(1), 13242 (2017).
  MedlineGoogle Scholar
• 67. Bianchi A, Lux F, Tillement O, Cremillieux Y. Contrast enhanced lung MRI in mice using ultra-short echo time radial imaging and intratracheally administrated Gd-DOTA-based nanoparticles. Magn. Reson. Med. 70(5), 1419–1426 (2013).
  Medline CASGoogle Scholar
• 68. Neuwelt A, Sidhu N, Hu CA, Mlady G, Eberhardt SC, Sillerud LO. Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammation. AJR Am. J. Roentgenol. 204(3), W302–313 (2015).
  MedlineGoogle Scholar
• 69. Al Faraj A, Sultana Shaik A, Pureza MA, Alnafea M, Halwani R. Preferential macrophage recruitment and polarization in LPS-induced animal model for COPD: noninvasive tracking using MRI. PLOS ONE 9(3), e90829 (2014).
  MedlineGoogle Scholar
• 70. Liu Y, Gunsten SP, Sultan DH et al. PET-based imaging of chemokine receptor 2 in experimental and disease-related lung inflammation. Radiology 283(3), 758–768 (2017).
  MedlineGoogle Scholar
• 71. Demura Y, Tsuchida T, Uesaka D et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur. J. Nucl. Med. Mol. Imaging 36(4), 632–639 (2009).
  MedlineGoogle Scholar
• 72. Dufort S, Bianchi A, Henry M et al. Nebulized gadolinium-based nanoparticles: a theranostic approach for lung tumor imaging and radiosensitization. Small 11(2), 215–221 (2015).
  Medline CASGoogle Scholar
• 73. Zhou J, Zhang Q, Zhang Q, Zhang Z. Nanobubble lung ultrasound application in the treatment of neonatal pneumonia. J. Nanosci. Nanotechnol. 21(2), 1244–1249 (2021).
  Medline CASGoogle Scholar
• 74. Wang B, Liu P, Huang H et al. Carbon dots up-regulate heme oxygenase-1 expression towards acute lung injury therapy. J. Mater. Chem. B 9(43), 9005–9011 (2021).
  Medline CASGoogle Scholar
• 75. Chenthamara D, Subramaniam S, Ramakrishnan SG et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater. Res. 23, 20 (2019).
  Medline CASGoogle Scholar
• 76. Zompatori M, Ciccarese F, Fasano L. Overview of current lung imaging in acute respiratory distress syndrome. Eur. Respir. Rev. 23(134), 519–530 (2014).
  MedlineGoogle Scholar
• 77. Purandare NC, Rangarajan V. Imaging of lung cancer: implications on staging and management. Indian J. Radiol. Imaging 25(2), 109–120 (2015).
  MedlineGoogle Scholar
• 78. Tsang VTC, Li X, Wong TTW. A review of endogenous and exogenous contrast agents used in photoacoustic tomography with different sensing configurations. Sensors (Basel) 20(19), 5595 (2020).
  Medline CASGoogle Scholar
• 79. Amlan Chakraborty CS. Functionalized Nanoparticles in Pulmonary Disease Diagnosis. Academic Press, London, UK. doi:10.1016/B978-0-12-820658-4.00014-5303-321 (2020).
  Google Scholar
• 80. Bayram H, Suer H. Liposomes as potential nanocarriers for theranostic applications in chronic inflammatory lung diseases. Biomed. Biotechnol. Res. J. 1(1), 1–8 (2017).
  Google Scholar
• 81. Mody V, Siwale R, Singh A, Mody H. Introduction to metallic nanoparticles. J. Pharm. Bioallied Sci. 2(4), 282–289 (2010).
  Medline CASGoogle Scholar
• 82. Inui S, Fujikawa A, Jitsu M et al. Chest CT findings in cases from the cruise ship diamond princess with coronavirus disease (COVID-19). Radiol. Cardiothorac. Imaging 2(2), e200110 (2020).
  MedlineGoogle Scholar
• 83. Hollings N, Shaw P. Diagnostic imaging of lung cancer. Eur. Respir. J. 19(4), 722–742 (2002).
  Medline CASGoogle Scholar
• 84. Dorsey JF, Sun L, Joh DY et al. Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization. Transl. Cancer Res. 2(4), 280–291 (2013).
  Medline CASGoogle Scholar
• 85. Lodhi MS, Khan MT, Aftab S, Samra ZQ, Wang H, Wei DQ. A novel formulation of theranostic nanomedicine for targeting drug delivery to gastrointestinal tract cancer. Cancer Nanotechnol. 12(1), 26 (2021).
  CASGoogle Scholar
• 86. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new x-ray contrast agent. Br. J. Radiol. 79(939), 248–253 (2006).
  Medline CASGoogle Scholar
• 87. Lusic H, Grinstaff MW. X-ray-computed tomography contrast agents. Chem. Rev. 113(3), 1641–1666 (2013).
  Medline CASGoogle Scholar
• 88. Behzadi S, Serpooshan V, Tao W et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46(14), 4218–4244 (2017).
  Medline CASGoogle Scholar
• 89. Geiser M. Morphological aspects of particle uptake by lung phagocytes. Microsc. Res. Tech. 57(6), 512–522 (2002).
  MedlineGoogle Scholar
• 90. Gosens I, Post JA, De La Fonteyne LJ et al. Impact of agglomeration state of nano- and submicron sized gold particles on pulmonary inflammation. Part Fibre Toxicol. 7(1), 37 (2010).
  Medline CASGoogle Scholar
• 91. Geiser M, Quaile O, Wenk A et al. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part Fibre Toxicol. 10, 19 (2013).
  Medline CASGoogle Scholar
• 92. Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab. J. Chem. 12(7), 908–931 (2019).
  CASGoogle Scholar
• 93. Srinivasan M, Rajabi M, Mousa SA. Multifunctional nanomaterials and their applications in drug delivery and cancer therapy. Nanomaterials (Basel) 5(4), 1690–1703 (2015).
  Medline CASGoogle Scholar
• 94. Wang L, Rao Y, Liu X et al. Administration route governs the therapeutic efficacy, biodistribution and macrophage targeting of anti-inflammatory nanoparticles in the lung. J. Nanobiotechnol. 19(1), 56 (2021).
  Medline CASGoogle Scholar
• 95. Silvestri A, Zambelli V, Ferretti AM, Salerno D, Bellani G, Polito L. Design of functionalized gold nanoparticle probes for computed tomography imaging. Contrast Media Mol. Imaging 11(5), 405–414 (2016).
  Medline CASGoogle Scholar
• 96. Noriega-Luna B, Godínez LA, Rodríguez FJ et al. Applications of dendrimers in drug delivery agents, diagnosis, therapy, and detection. J. Nanomater. 2014, 1–19 (2014).
  Google Scholar
• 97. Cormode DP, Naha PC, Fayad ZA. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol. Imaging 9(1), 37–52 (2014).
  Medline CASGoogle Scholar
• 98. Karakoti AS, Monteiro-Riviere NA, Aggarwal R et al. Nanoceria as antioxidant: synthesis and biomedical applications. JOM (1989) 60(3), 33–37 (2008).
  Medline CASGoogle Scholar
• 99. Naha PC, Hsu JC, Kim J et al. Dextran-coated cerium oxide nanoparticles: a computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory bowel disease. ACS Nano 14(8), 10187–10197 (2020).
  Medline CASGoogle Scholar
• 100. Bhushan B, Gopinath P. Antioxidant nanozyme: a facile synthesis and evaluation of the reactive oxygen species scavenging potential of nanoceria encapsulated albumin nanoparticles. J. Mater. Chem. B 3(24), 4843–4852 (2015).
  Medline CASGoogle Scholar
• 101. Arya A, Sethy NK, Singh SK, Das M, Bhargava K. Cerium oxide nanoparticles protect rodent lungs from hypobaric hypoxia-induced oxidative stress and inflammation. Int. J. Nanomed. 8, 4507–4520 (2013).
  MedlineGoogle Scholar
• 102. Oztas E, Abudayyak M, Aykanat B, Can Z, Baram E, Ozhan G. Bismuth oxide nanoparticles induced oxidative stress-related inflammation in SH-SY5Y cell line. Istanbul J. Pharm. doi:10.26650/IstanbulJPharm.2019.19020 (2019).
  Google Scholar
• 103. Manuja A, Kumar B, Kumar R et al. Metal/metal oxide nanoparticles: toxicity concerns associated with their physical state and remediation for biomedical applications. Toxicol. Rep. 8, 1970–1978 (2021).
  Medline CASGoogle Scholar
• 104. Porra L, Degrugilliers L, Broche L et al. Quantitative imaging of regional aerosol deposition, lung ventilation and morphology by synchrotron radiation CT. Sci. Rep. 8(1), 3519 (2018).
  Medline CASGoogle Scholar
• 105. Romei C, Turturici L, Tavanti L et al. The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review. Eur. Respir. Rev. 27(150), 180062 (2018).
  MedlineGoogle Scholar
• 106. Lodhi MS, Shaheen A, Khan MT, Shafiq MI, Samra ZQ, Wei DQ. A novel method of affinity purification and characterization of polygalacturonase of Aspergillus flavus by galacturonic acid engineered magnetic nanoparticle. Food Chem. 372, 131317 (2022).
  Medline CASGoogle Scholar
• 107. Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK. MRI contrast agents: classification and application (review). Int. J. Mol. Med. 38(5), 1319–1326 (2016).
  Medline CASGoogle Scholar
• 108. Falk Delgado A, Van Westen D, Nilsson M et al. Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging – a comprehensive overview. Insights Imaging 10(1), 84 (2019).
  MedlineGoogle Scholar
• 109. Lodhi MS, Khalid F, Khan MT et al. A novel method of magnetic nanoparticles functionalized with anti-folate receptor antibody and methotrexate for antibody mediated targeted drug delivery. Molecules 27(1), 261 (2022). •• Engineering magnetic nanoparticles with antibodies for targeted nanomedicine.
  Medline CASGoogle Scholar
• 110. Fisher MJ, Williamson DJ, Burslem GM et al. Trivalent Gd-DOTA reagents for modification of proteins. RSC Adv. 5(116), 96194–96200 (2015).
  Medline CASGoogle Scholar
• 111. Bitar R, Leung G, Perng R et al. MR pulse sequences: what every radiologist wants to know but is afraid to ask. Radiographics 26(2), 513–537 (2006).
  MedlineGoogle Scholar
• 112. Ma YJ, Jang H, Chang EY et al. Ultrashort echo time (UTE) magnetic resonance imaging of myelin: technical developments and challenges. Quant. Imaging Med. Surg. 10(6), 1186–1203 (2020).
  MedlineGoogle Scholar
• 113. Kaur G, Narang RK, Rath G, Goyal AK. Advances in pulmonary delivery of nanoparticles. Artif. Cells Blood Substit. Immobil. Biotechnol. 40(1-2), 75–96 (2012).
  Medline CASGoogle Scholar
• 114. Rastogi A, Yadav K, Mishra A et al. Early diagnosis of lung cancer using magnetic nanoparticles-integrated systems. Nanotechnol. Rev. 11(1), 544–574 (2022).
  CASGoogle Scholar
• 115. Huang Y, Hsu JC, Koo H, Cormode DP. Repurposing ferumoxytol: diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics 12(2), 796–816 (2022).
  Medline CASGoogle Scholar
• 116. Moller W, Felten K, Sommerer K et al. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am. J. Respir. Crit. Care Med. 177(4), 426–432 (2008).
  MedlineGoogle Scholar
• 117. Chakraborty A, Royce SG, Selomulya C, Plebanski M. A novel approach for non-invasive lung imaging and targeting lung immune cells. Int. J. Mol. Sci. 21(5), 1613 (2020).
  Medline CASGoogle Scholar
• 118. Liu D, Chen Y, Li F et al. Sinapultide-loaded microbubbles combined with ultrasound to attenuate lipopolysaccharide-induced acute lung injury in mice. Drug Des. Devel. Ther. 14, 5611–5622 (2020). •• Pulmonary surfactant-loaded microbubbles for lung injury diseases.
  Medline CASGoogle Scholar
• 119. Feshitan JA, Legband ND, Borden MA, Terry BS. Systemic oxygen delivery by peritoneal perfusion of oxygen microbubbles. Biomaterials 35(9), 2600–2606 (2014).
  Medline CASGoogle Scholar
• 120. Sugiyama MG, Mintsopoulos V, Raheel H et al. Lung ultrasound and microbubbles enhance aminoglycoside efficacy and delivery to the lung in Escherichia coli-induced pneumonia and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 198(3), 404–408 (2018).
  MedlineGoogle Scholar
• 121. Helfield B, Zou Y, Matsuura N. Acoustically-stimulated nanobubbles: opportunities in medical ultrasound imaging and therapy. Front. Physics 9, 654374 (2021).
  Google Scholar
• 122. Paknahad AA, Kerr L, Wong DA, Kolios MC, Tsai SSH. Biomedical nanobubbles and opportunities for microfluidics. RSC Adv. 11(52), 32750–32774 (2021). • Addresses the development of a microfluidic toolbox-based nanobubble platform.
  Medline CASGoogle Scholar
• 123. Zhang H, Ji Z, Xia T et al. Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. ACS Nano 6(5), 4349–4368 (2012).
  Medline CASGoogle Scholar
• 124. Kashefi A, Kuo J, Shelton DK. Molecular imaging in pulmonary diseases. AJR Am. J. Roentgenol. 197(2), 295–307 (2011).
  MedlineGoogle Scholar
• 125. Portnoy E, Lecht S, Lazarovici P, Danino D, Magdassi S. Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomedicine 7(4), 480–488 (2011).
  Medline CASGoogle Scholar
• 126. Desu HR, Wood GC, Thoma LA. Non-invasive detection of lung inflammation by near-infrared fluorescence imaging using bimodal liposomes. J. Fluoresc. 26(1), 241–253 (2016).
  Medline CASGoogle Scholar
• 127. Elhissi A. Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design. Curr. Pharm. Des. 23(3), 362–372 (2017).
  Medline CASGoogle Scholar
• 128. D'angelo I, Conte C, Miro A, Quaglia F, Ungaro F. Pulmonary drug delivery: a role for polymeric nanoparticles? Curr. Top. Med. Chem. 15(4), 386–400 (2015).
  MedlineGoogle Scholar
• 129. Alivisatos AP. Semiconductor clusters, nanocrystals, and quantum dots. Science 271(5251), 933–937 (1996).
  CASGoogle Scholar
• 130. Gil HM, Price TW, Chelani K, Bouillard JG, Calaminus SDJ, Stasiuk GJ. NIR-quantum dots in biomedical imaging and their future. iScience 24(3), 102189 (2021).
  Medline CASGoogle Scholar
• 131. Nikazar S, Sivasankarapillai VS, Rahdar A, Gasmi S, Anumol PS, Shanavas MS. Revisiting the cytotoxicity of quantum dots: an in-depth overview. Biophys. Rev. 12(3), 703–718 (2020).
  MedlineGoogle Scholar
• 132. Roberts JR, Antonini JM, Porter DW et al. Lung toxicity and biodistribution of Cd/Se-ZnS quantum dots with different surface functional groups after pulmonary exposure in rats. Part Fibre Toxicol. 10, 5 (2013).
  Medline CASGoogle Scholar
• 133. Liu SY, Yan AM, Guo WY et al. Human neutrophil elastase activated fluorescent probe for pulmonary diseases based on fluorescence resonance energy transfer using CdSe/ZnS quantum dots. ACS Nano 14(4), 4244–4254 (2020).
  Medline CASGoogle Scholar
• 134. Nair A, Haponiuk JT, Thomas S, Gopi S. Natural carbon-based quantum dots and their applications in drug delivery: a review. Biomed. Pharmacother. 132, 110834 (2020).
  Medline CASGoogle Scholar
• 135. Weiss M, Fan J, Claudel M, Lebeau L, Pons F, Ronzani C. Combined in vitro and in vivo approaches to propose a putative adverse outcome pathway for acute lung inflammation induced by nanoparticles: a study on carbon dots. Nanomaterials (Basel) 11(1), 180 (2021).
  Medline CASGoogle Scholar
• 136. Narasimhan AK, Lakshmi BS, Santra TS, Rao MSR, Krishnamurthi G. Oxygenated graphene quantum dots (GQDs) synthesized using laser ablation for long-term real-time tracking and imaging. RSC Adv. 7(85), 53822–53829 (2017).
  CASGoogle Scholar
• 137. Cao J, Zhu B, Zheng K et al. Recent progress in NIR-II contrast agent for biological imaging. Front. Bioeng. Biotechnol. 7, 487 (2020).
  MedlineGoogle Scholar
• 138. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin. Nucl. Med. 39(2), 124–145 (2009).
  MedlineGoogle Scholar
• 139. Majumdar S, Murphy PM. Chemokine regulation during epidemic coronavirus infection. Front. Pharmacol. 11, 600369 (2020).
  Medline CASGoogle Scholar
• 140. Chen L, Deng H, Cui H et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9(6), 7204–7218 (2017).
  MedlineGoogle Scholar
• 141. Prasher P, Sharma M, RW P et al. Can dextran-based nanoparticles mitigate inflammatory lung diseases? Future Med. Chem. doi:10.4155/fmc-2021-0218 (2021).
  Google Scholar
• 142. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354(6), 610–621 (2006).
  Medline CASGoogle Scholar
• 143. Corcoran TE. Imaging in aerosol medicine. Respir. Care 60(6), 850–857 (2015).
  MedlineGoogle Scholar
• 144. Zhang X, Liu X, Guo Y, Wu FG. Strategies for visualizing inflammation. View 2(1), 20200025 (2020).
  Google Scholar
• 145. Pellico J, Lechuga-Vieco AV, Almarza E et al. In vivo imaging of lung inflammation with neutrophil-specific 68Ga nano-radiotracer. Sci. Rep. 7(1), 13242 (2017).
  MedlineGoogle Scholar
• 146. Chen X, Song J, Chen X, Yang H. X-ray-activated nanosystems for theranostic applications. Chem. Soc. Rev. 48(11), 3073–3101 (2019).
  Medline CASGoogle Scholar
• 147. Dai X, Cheng K, Zhao W, Xing L. High-speed x-ray-induced luminescence computed tomography. J. Biophotonics 13(9), e202000066 (2020).
  MedlineGoogle Scholar
• 148. Li Y, Samant P, Cochran C et al. The feasibility study of XACT imaging for characterizing osteoporosis. Med. Phys. doi:10.1002/mp.15906 (2022).
  Google Scholar
• 149. Wu S, Li Y, Ding W, Xu L, Ma Y, Zhang L. Recent advances of persistent luminescence nanoparticles in bioapplications. Nanomicro. Lett. 12(1), 70 (2020).
  Medline CASGoogle Scholar
• 150. Pogue BW, Zhang R, Cao X et al. Review of in vivo optical molecular imaging and sensing from x-ray excitation. J. Biomed. Opt. 26(1), 010902 (2021).
  Medline CASGoogle Scholar
• 151. Kamkaew A, Chen F, Zhan Y, Majewski RL, Cai W. Scintillating nanoparticles as energy mediators for enhanced photodynamic therapy. ACS Nano 10(4), 3918–3935 (2016).
  Medline CASGoogle Scholar
• 152. Pei P, Chen Y, Sun C et al. X-ray-activated persistent luminescence nanomaterials for NIR-II imaging. Nat. Nanotechnol. 16(9), 1011–1018 (2021).
  Medline CASGoogle Scholar
• 153. Narasimhan AK, Balasubramanian SL, Krishnamurthi G. Influence of europium (Eu) doped tantalum oxide nanoparticles (TaOx NPs): a potential contrast agent. Mater. Lett. 300, 130214 (2021). • Metal-oxide-doped nanoparticles for x-ray-excited optical imaging.
  CASGoogle Scholar
• 154. Parekh M, Donuru A, Balasubramanya R, Kapur S. Review of the chest CT differential diagnosis of ground-glass opacities in the COVID era. Radiology 297(3), E289–E302 (2020).
  MedlineGoogle Scholar
• 155. Agrebi S, Larbi A. Use of artificial intelligence in infectious diseases. In: Artificial Intelligence in Precision Health. Stacy Masucci (Ed.)., NY, USA, 415–438 (2020).
  Google Scholar
• 156. Burki TK. The role of AI in diagnosing lung diseases. Lancet Respir. Med. 7(12), 1015–1016 (2019).
  MedlineGoogle Scholar
• 157. Ciompi F, Chung K, Van Riel SJ et al. Towards automatic pulmonary nodule management in lung cancer screening with deep learning. Sci. Rep. 7, 46479 (2017).
  Medline CASGoogle Scholar
• 158. Abadia AF, Yacoub B, Stringer N et al. Diagnostic accuracy and performance of artificial intelligence in detecting lung nodules in patients with complex lung disease: a noninferiority study. J. Thorac. Imaging 37(3), 154–161 (2022).
  MedlineGoogle Scholar
• 159. San Jose Estepar R. Artificial intelligence in functional imaging of the lung. Br. J. Radiol. 95(1132), 20210527 (2022).
  MedlineGoogle Scholar
• 160. Harmon SA, Sanford TH, Xu S et al. Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. Nat. Commun. 11(1), 4080 (2020).
  Medline CASGoogle Scholar
• 161. Feng Y, Wang Y, Zeng C, Mao H. Artificial intelligence and machine learning in chronic airway diseases: focus on asthma and chronic obstructive pulmonary disease. Int. J. Med. Sci. 18(13), 2871–2889 (2021).
  MedlineGoogle Scholar
• 162. Makela K, Mayranpaa MI, Sihvo HK et al. Artificial intelligence identifies inflammation and confirms fibroblast foci as prognostic tissue biomarkers in idiopathic pulmonary fibrosis. Hum. Pathol. 107, 58–68 (2021).
  Medline CASGoogle Scholar
• 163. Espinoza JL, Dong LT. Artificial intelligence tools for refining lung cancer screening. J. Clin. Med. 9(12), 3860 (2020).
  Medline CASGoogle Scholar
• 164. Reis M, Gusev F, Taylor NG et al. Machine-learning-guided discovery of (19)F MRI agents enabled by automated copolymer synthesis. J. Am. Chem. Soc. 143(42), 17677–17689 (2021). • Machine-learning-guided material development.
  Medline CASGoogle Scholar